DE60109922D1 - Therapeutische verbindungen gegen eierstockkrebs - Google Patents

Therapeutische verbindungen gegen eierstockkrebs

Info

Publication number
DE60109922D1
DE60109922D1 DE60109922T DE60109922T DE60109922D1 DE 60109922 D1 DE60109922 D1 DE 60109922D1 DE 60109922 T DE60109922 T DE 60109922T DE 60109922 T DE60109922 T DE 60109922T DE 60109922 D1 DE60109922 D1 DE 60109922D1
Authority
DE
Germany
Prior art keywords
therapeutic compounds
compounds against
compounds
against egg
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60109922T
Other languages
English (en)
Inventor
A Nicolette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of DE60109922D1 publication Critical patent/DE60109922D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Feed For Specific Animals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60109922T 2000-05-31 2001-05-30 Therapeutische verbindungen gegen eierstockkrebs Expired - Lifetime DE60109922D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20938800P 2000-05-31 2000-05-31
US25700700P 2000-12-20 2000-12-20
PCT/US2001/017454 WO2001092306A2 (en) 2000-05-31 2001-05-30 Therapeutic compounds for ovarian cancer

Publications (1)

Publication Number Publication Date
DE60109922D1 true DE60109922D1 (de) 2005-05-12

Family

ID=26904120

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60109922T Expired - Lifetime DE60109922D1 (de) 2000-05-31 2001-05-30 Therapeutische verbindungen gegen eierstockkrebs

Country Status (8)

Country Link
US (2) US6737062B2 (de)
EP (1) EP1284997B1 (de)
JP (1) JP2004503217A (de)
AT (1) ATE292640T1 (de)
AU (1) AU2001265188A1 (de)
CA (1) CA2410895A1 (de)
DE (1) DE60109922D1 (de)
WO (1) WO2001092306A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004514412A (ja) * 2000-05-31 2004-05-20 ジェンザイム・コーポレーション 卵巣癌のための治療化合物
EP1284997B1 (de) 2000-05-31 2005-04-06 Genzyme Corporation Therapeutische verbindungen gegen eierstockkrebs
WO2002070003A1 (en) * 2001-02-14 2002-09-12 Genzyme Corporation Altered peptide ligands
WO2002080845A2 (en) * 2001-04-04 2002-10-17 Genzyme Corporation Novel eps8 compounds for therapy and diagnosis and methods for using same
WO2003050307A1 (en) * 2001-12-05 2003-06-19 Genzyme Corporation Compounds for therapy and diagnosis and methods for using same
WO2003068925A2 (en) * 2002-02-11 2003-08-21 Mosca Joseph D Production of a protein delivery system for in vivo therapeutic treatment
JP2005191530A (ja) * 2003-12-03 2005-07-14 Sumitomo Electric Ind Ltd 発光装置
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
JP5393691B2 (ja) * 2007-10-09 2014-01-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 急性ヒト骨髄性白血病細胞を死滅させるトロンボポエチン受容体作用薬（ＴｐｏＲＡ）

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5688657A (en) * 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
WO1992013878A2 (en) 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
JPH07101999A (ja) 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
DE19817946A1 (de) 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Uterus-Normalgewebe
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
AU2001233114A1 (en) 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
EP1284997B1 (de) 2000-05-31 2005-04-06 Genzyme Corporation Therapeutische verbindungen gegen eierstockkrebs

Also Published As

Publication number Publication date
EP1284997B1 (de) 2005-04-06
WO2001092306A3 (en) 2002-08-08
US20030175252A1 (en) 2003-09-18
ATE292640T1 (de) 2005-04-15
WO2001092306A2 (en) 2001-12-06
EP1284997A2 (de) 2003-02-26
US20050048068A1 (en) 2005-03-03
CA2410895A1 (en) 2001-12-06
JP2004503217A (ja) 2004-02-05
AU2001265188A1 (en) 2001-12-11
US6737062B2 (en) 2004-05-18

Similar Documents

Publication Publication Date Title
FI1897548T4 (fi) T-solujen säätely
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
IL214325A (en) Antibody against cmet, a drug that includes and uses it
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
AU9399501A (en) Therapeutic antibodies
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201270625A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
EA200601761A1 (ru) Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения
CR11399A (es) ANTICUERPOS ANTI-IL-12/23p40, EPITOPES, FORMULACIONES, COMPOSICIONES, METODOS Y USOS
ATE497392T1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
WO2008034074A3 (en) Cyclosphosphamide in combination with anti-idiotypic vaccines
DE60109922D1 (de) Therapeutische verbindungen gegen eierstockkrebs
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
DE60116068D1 (de) Therapeutische anti-cytomegalovirus verbindungen
WO2001068677A3 (en) Derivatives of breast canacer antigen her-2 for therapeutical use
ATE525401T1 (de) Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene
DE60111538D1 (de) Therapeutische verbindungen gegen eierstockkrebs
WO2002012272A3 (en) Therapeutic anti-melanoma compounds
WO2001070767A3 (en) Therapeutic anti-melanoma compounds
WO2001092307A3 (en) Therapeutic compounds for ovarian cancer
WO2003037264A3 (en) Therapeutic anti-hiv (vpr) compounds
WO2001092294A3 (en) Therapeutic anti-melanoma compounds
WO2004071414A3 (en) Therapeutic anti-hcv (al9) compounds
WO2003051285A3 (en) Therapeutic anti-hiv (iv9) compounds

Legal Events

Date Code Title Description
8332 No legal effect for de